Maria brings over 25 years of professional biotech and pharmaceutical experience, the majority of which has been in oncology. Most recently, she held a senior leadership role at ADC Therapeutics, responsible for Clinical Operations, Science, and Medical Writing, and was a key contributor to the successful approval of Zynlonta® within 6 years of initiating first-in-human clinical trials. Maria consulted as a Clinical Scientist at Sanofi Oncology and Aveo Oncology, and began her career at Genetics Institute, taking roles of increasing responsibility and scope as the company became part of Wyeth’s research division. At the time Wyeth was acquired by Pfizer, Maria was a clinical program leader for Torisel® and various early development compounds.
Maria received a BA from the University of Massachusetts in Amherst, and an MS from the Massachusetts General Hospital Institute of Health Professions.